Early identification of persons with rheumatoid arthritis Empowering persons with rheumatoid arthritis Developing efficient, cost-effective and evidence-based clinical care for persons with rheumatoid arthritis.
Background
This document is intended to help and support the rheumatology team by providing a statement of the minimum standard of care requirements for persons with rheumatoid arthritis. It can also act as the formal record of standards of care as part of the clinical governance process of any rheumatology unit.
Objectives
The aim is to develop nationally accepted measures for the delivery of care for persons with rheumatoid arthritis. These should usually be recorded as part of the normal clinical care of the patient. Specific situations in which patients may require closer than average monitoring are also discussed. The aim is to obtain the best quality of care within the resources available. The need for multidisciplinary team care is also addressed.
The standards address the following areas:
outcome measures special clinical circumstances departmental structure.
Review of Standards
The Standards will be reviewed in Autumn 2006 to take into account changes in the evidence and consensus management of rheumatoid arthritis.
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Production of document
The headings used in this set of Standards were derived following discussions within the committee to reflect the important steps in delivering care for persons with rheumatoid arthritis. Each statement has been assessed against available evidence or consensus reached.
Standards of care for rheumatoid arthritis

Outcome measures Standard 1: Identification of persons with rheumatoid arthritis
The rheumatology department should see all patients with a likely diagnosis of rheumatoid arthritis within 12 weeks of referral, where this is indicated in the general practitioner's referral letter (C) [letters in parentheses refer to the grades of recommendation listed in Appendix 3] [1].
Standard 2: Empowering persons with rheumatoid arthritis
All persons with rheumatoid arthritis will be encouraged to participate fully in the management of their disease and to take a leading role in the multidisciplinary team. This should include access to self-management programmes, local support groups and appropriate information to manage their own disease. This management should take into account not only the goal of controlling the activity of the disease, thereby reducing the pain, damage and disability of the disease, but also the psychological, employment and educational opportunities, family and social impact of the disease (B) [2] .
Clinical care of persons with rheumatoid arthritis Access to voluntary organizations involved in rheumatoid arthritis management, counselling services, the pain management team, neurosurgery, plastic surgery, neurophysiology and the wheelchair service should also be available. When clinically indicated, access to a member of the multidisciplinary team should be available within 6 weeks of referral (B) [2] .
Standard 4: Prescription and monitoring of treatments used to manage rheumatoid disease
The prescription to persons with rheumatoid arthritis of nonsteroid anti-inflammatory drugs (NSAIDs), including COX II and biological agents, should follow NICE guidance (A) [3, 4] .
Systems should be in place to effectively: assess all patients who might be considered to be appropriate for biological therapy as defined by the NICE and BSR guidelines register, once consent is obtained, all persons receiving biological agents with the BSR registry monitor access to therapy and clinical response identify side-effects of therapy and other drugs, including DMARDs, used to manage rheumatoid arthritis. The multidisciplinary team should undertake this monitoring (C) [5] .
Standard 5: Annual review
All persons with rheumatoid arthritis should have a formal annual assessment of disease activity, manifestations of extra-articular disease, the effects of the disease on quality of life, employment status, an assessment of disability, drug-related complications and any comorbid conditions. The annual review should identify if any events have occurred which would put the person with rheumatoid arthritis at risk; e.g. introduction of infection at the time of joint injection, and bone marrow damage as a result of drug therapy. This process can be undertaken by a member of the multidisciplinary team such as the rheumatology practitioner (C) [5] .
Standard 6: Prevention of steroid-induced osteoporosis
All persons 65 years or older with rheumatoid arthritis taking doses of steroids (usually prednisolone) for 12 weeks or more should be offered bone-protective therapy. Persons under 65 with no previous fragility fracture should be offered DXA scanning to assess the risk of osteoporosis. If, in persons under 65 with rheumatoid arthritis, there is a previous fragility fracture or incident fracture during glucocorticoid therapy, bone protective therapy should be considered (A) [6] .
Standard 7: Pain management
All persons with rheumatoid arthritis should be given the opportunity to discuss how their pain might best be managed. The advice of a pain management team should be available. Persons with rheumatoid arthritis should understand the benefits and sideeffects of analgesic and anti-inflammatory drugs and of other drugs used to achieve better pain control, such as amitriptyline and carbamazepine. They should also know about alternative techniques of effective pain management, including trans cutaneous nerve stimulation (TENS) and behavioural approaches (A) [7] .
Standard 8: Collaboration with orthopaedic surgeons
Persons with rheumatoid arthritis who have unacceptable levels of pain despite all previously mentioned approaches and who have significant loss of range of movement of a joint or who have significant limitation of activities of daily living because of structural damage of one or more joints should be offered the advice of and treatment from an orthopaedic surgeon with a special interest in rheumatoid arthritis (B) [2] . 
Special clinical circumstances
Standard 10: Pregnancy for persons with rheumatoid arthritis
All persons with rheumatoid arthritis who wish to become pregnant should be offered adequate and appropriate advice from a rheumatologist, an obstetrician and the multidisciplinary team. In special circumstances, such persons might be cared for in a special clinic; for example, persons with the antiphospholipid (Hughes) syndrome. Males with rheumatoid arthritis who wish to become a father should also be offered specialist advice (C) [8] .
The rheumatology service
Development of patient-centred care
Standard 11: Involvement of users and carers People with rheumatoid arthritis who use the rheumatology service and their carers will be encouraged to be actively involved in the development, monitoring and evaluation of services (C) [9] .
Standard 12: Access to facilities
Where persons with disabilities need access to primary care or hospital services, specially designed facilities should be available, including disabled access to all departments and to washing and toilet facilities. Facilities for wheelchair access must be provided (C) [10].
Standard 13: In-patient management All persons with rheumatoid arthritis who are admitted to a hospital should have due account taken of any symptoms or disabilities that are due to rheumatoid arthritis or other causes, and, if they are admitted under the care of other specialists, should be offered referral to a rheumatologist. Planning for their admission should take into account any disability. Special arrangements may be necessary for the admission of young persons to appropriate units (C) [9] .
Standard 14: Out-patient services
For persons with rheumatoid arthritis, 30 minutes should be made available for the initial consultation with a consultantled team. Fifteen minutes should be available for subsequent appointments.
If the person with rheumatoid arthritis sees a trainee or another member of the clinical team (for example, a rheumatology practitioner), there should be an opportunity, if appropriate, to discuss the management with the consultant. Where teaching is undertaken in clinic, the number of patients attending the clinic should be reduced by 25% (C) [11] .
Applicability and utility
The potential organizational barriers to the successful implementation of these standards include:
identification and funding of the members of the multidisciplinary team funding of the COX II and biological therapies ensuring appropriate staffing to enable data collection for the annual review and the other audit projects ensuring that the physical environment of the service providers meets the requirements of people with disabilities implementing the Royal College of Physicians (RCP) guidance on the numbers of patients seen in the out-patient department. These Standards were commissioned by the BSR Clinical Affairs Committee. The committee has not sought or obtained any external funding for this work. All the authors have declared and provided details of any conflicts of interest (see Appendix 4).
Appendix 1. The future
The management of rheumatoid arthritis is changing rapidly. It is expected that, through ongoing research, new approaches to the management of rheumatoid arthritis will change the course of the disease radically in the near future.
To achieve this improvement in the quality of life, it is expected that evidence will become available which will suggest that: the use of biological agents in patients with early disease is effective in those patients, who can be identified as likely to have severe destructive disease. It will therefore be necessary to see people with early rheumatoid arthritis within 6 weeks of presentation control of comorbid conditions, such as ischaemic heart disease, hyperlipidaemia and hypertension, will become increasingly important. 
